Acquisition Impact Options MD was acquired by Resilience Lab in August 2024, signaling a consolidation in treatment-resistant depression care. This suggests a broader care delivery network and potential cross-sell opportunities for Resilience Lab services, referral pathways, and joint programs targeting TRD patients.

Scale Opportunities Despite a small internal team, the company has demonstrated rapid clinical impact via AI-driven treatment matching. Engage with the parent organization (Resilience Lab) to explore scale-ready solutions, clinical workflows, and implementation support that can be deployed across larger networks.

Financial signals Revenue range of one to ten million and total funding around four million pre- and post-acquisition indicate growth potential with efficiency improvements. Propose bundled digital health tools, ongoing platform licensing, and expanded telehealth capabilities to drive higher patient throughput.

Technology stack Usage of AI-infused matching, Stripe for payments, Node.js, and standard web tooling suggests a modern, cloud-based delivery model. Sales pitches can emphasize scalable AI-driven treatment optimization, secure payments, and API-ready integrations for partner clinics and payers.

Market positioning Focused on treatment-resistant illnesses with a telehealth-first approach positions Options MD and now Resilience Lab within a high-need, underserved segment. Target payers, managed care organizations, and clinics seeking specialized TRD programs, outcome-based contracts, and enhanced access to advanced therapeutics.